InflaRx (IFRX) News Today → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free IFRX Stock Alerts $1.46 +0.02 (+1.39%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 21, 2024 | finance.yahoo.comInflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsMay 21, 2024 | globenewswire.comInflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other ImmunomodulatorsMay 10, 2024 | markets.businessinsider.comInflaRx’s Promising Future: Buy Rating Reaffirmed Amidst Pipeline Progress and Upcoming R&D InsightsMay 9, 2024 | markets.businessinsider.comInflaRx Buy Rating: Strong Financials and High Potential of Gohibic for PG TreatmentMay 9, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reiterated a "buy" rating and set a $8.00 price objective on shares of InflaRx in a report on Thursday.May 8, 2024 | investorplace.comIFRX Stock Earnings: InflaRx Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | finance.yahoo.comInflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | globenewswire.comInflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | msn.comInflaRx Q1 2024 Earnings PreviewMay 1, 2024 | marketbeat.comInflaRx (IFRX) to Release Quarterly Earnings on WednesdayInflaRx (NASDAQ:IFRX) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.April 30, 2024 | finance.yahoo.comInflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024April 24, 2024 | globenewswire.comInflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventApril 15, 2024 | marketbeat.comShort Interest in InflaRx (NASDAQ:IFRX) Grows By 22.9%InflaRx (NASDAQ:IFRX - Get Free Report) saw a significant increase in short interest in the month of March. As of March 31st, there was short interest totalling 389,100 shares, an increase of 22.9% from the March 15th total of 316,700 shares. Based on an average daily volume of 234,200 shares, the short-interest ratio is currently 1.7 days.April 2, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest Up 7.8% in MarchInflaRx (NASDAQ:IFRX - Get Free Report) saw a large growth in short interest in March. As of March 15th, there was short interest totalling 316,700 shares, a growth of 7.8% from the February 29th total of 293,900 shares. Based on an average daily trading volume, of 255,800 shares, the days-to-cover ratio is currently 1.2 days.March 22, 2024 | markets.businessinsider.comBuy Rating Justified for InflaRx Despite Earnings Miss: Financial Stability and INF904’s Market PotentialMarch 22, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $8.00 price objective on shares of InflaRx in a report on Friday.March 21, 2024 | investorplace.comIFRX Stock Earnings: InflaRx Misses EPS, Misses Revenue for Q4 2023March 21, 2024 | globenewswire.comInflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansMarch 20, 2024 | benzinga.com6IFRX : Earnings Preview: InflaRxMarch 19, 2024 | globenewswire.comInflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024March 18, 2024 | marketbeat.comInflaRx (NASDAQ:IFRX) Short Interest Down 9.3% in FebruaryInflaRx (NASDAQ:IFRX - Get Free Report) was the recipient of a significant decrease in short interest in February. As of February 29th, there was short interest totalling 293,900 shares, a decrease of 9.3% from the February 14th total of 324,200 shares. Based on an average trading volume of 278,300 shares, the days-to-cover ratio is presently 1.1 days.March 6, 2024 | finance.yahoo.comIs InflaRx (NASDAQ:IFRX) In A Good Position To Deliver On Growth Plans?March 1, 2024 | marketbeat.com683 Capital Management LLC Increases Stock Holdings in InflaRx (NASDAQ:IFRX)683 Capital Management LLC lifted its holdings in InflaRx (NASDAQ:IFRX - Free Report) by 17.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,350,000 shares of the company's stock after puFebruary 22, 2024 | investing.comInflaRx N.V. (IFRX)February 22, 2024 | finance.yahoo.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 22, 2024 | globenewswire.comInflaRx Appoints Jan Medina as Head of Investor RelationsFebruary 17, 2024 | finance.yahoo.comIFRX Apr 2024 2.500 callFebruary 14, 2024 | marketbeat.comShort Interest in InflaRx (NASDAQ:IFRX) Decreases By 19.5%InflaRx (NASDAQ:IFRX - Get Free Report) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 307,000 shares, a decline of 19.5% from the January 15th total of 381,200 shares. Based on an average daily volume of 256,200 shares, the short-interest ratio is currently 1.2 days.January 25, 2024 | markets.businessinsider.comBuy Recommendation for InflaRx Amidst Strategic Initiatives and Promising Clinical AdvancesJanuary 25, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Initiation of its Commitment Program for GOHIBIC(vilobelimab) to Help Broaden Access for Eligible PatientsJanuary 25, 2024 | finance.yahoo.comInflaRx N.V.'s (NASDAQ:IFRX) top owners are individual investors with 55% stake, while 23% is held by institutionsJanuary 25, 2024 | finance.yahoo.comInflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsJanuary 6, 2024 | markets.businessinsider.comInflaRx’s Promising INF904 Phase 1 Results Prompt Buy RatingJanuary 4, 2024 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904January 4, 2024 | markets.businessinsider.comInflaRx's MAD Part Phase 1 Trial For INF904 Reports Positive ResultsJanuary 4, 2024 | finance.yahoo.comInflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904December 1, 2023 | finance.yahoo.comHere's Why InflaRx N.V. (IFRX) Looks Ripe for Bottom FishingNovember 28, 2023 | finance.yahoo.comAfter Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)November 20, 2023 | morningstar.comInflaRx NV IFRXNovember 7, 2023 | markets.businessinsider.comBuy Rating for InflaRx: Potential Breakthrough PG Treatment and Promising Revenue ForecastsNovember 6, 2023 | finance.yahoo.comInflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerNovember 6, 2023 | finance.yahoo.comInflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNovember 3, 2023 | msn.comIFRX, LIXT and IOAC are among pre market gainersNovember 3, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cross Country Healthcare (CCRN), InflaRx (IFRX) and Elevation Oncology (ELEV)November 1, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNovember 1, 2023 | msn.comInflaRx GAAP EPS of -€0.13November 1, 2023 | finance.yahoo.comInflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateOctober 10, 2023 | finance.yahoo.comLoss-Making InflaRx N.V. (NASDAQ:IFRX) Expected To Breakeven In The Medium-TermSeptember 13, 2023 | finance.yahoo.comWe Think InflaRx (NASDAQ:IFRX) Can Afford To Drive Business GrowthSeptember 11, 2023 | finanznachrichten.deInflaRx N.V.: InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904 Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW IFRX Media Mentions By Week IFRX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IFRX News Sentiment▼0.650.85▲Average Medical News Sentiment IFRX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IFRX Articles This Week▼31▲IFRX Articles Average Week Get InflaRx News Delivered to You Automatically Sign up to receive the latest news and ratings for IFRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alto Neuroscience News Today Nkarta News Today UroGen Pharma News Today Q32 Bio News Today Nanobiotix News Today Atea Pharmaceuticals News Today Kamada News Today XOMA News Today ADC Therapeutics News Today CorMedix News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IFRX) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeYou won't believe what Citigroup just did to it's depositorsAmerican AlternativeWARNING about the death of the U.S. dollar…Colonial MetalsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InflaRx Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
